Current studies show that approximately 5- to 17-fold lower plasma EPO levels were measured in CKD patients who were successfully treated with HIF-PH inhibitors compared to those receiving epoetin alfa (Holdstock et al., 2016; Provenzano et al., 2016). Here, EPO is linked to chronic kidney disease.